Early risk predictors of acute kidney injury and short-term survival during Impella support in cardiogenic shock
- PMID: 39080441
- PMCID: PMC11289486
- DOI: 10.1038/s41598-024-68376-w
Early risk predictors of acute kidney injury and short-term survival during Impella support in cardiogenic shock
Abstract
Acute kidney injury (AKI) is one of the most frequent and prognostic-relevant complications of cardiogenic shock (CS) complicating myocardial infarction (MI). Mechanical circulatory assist devices (MCS) like left ventricular Impella microaxial pump have increasingly been used in the last decade for stabilization of hemodynamics in those patients. Moreover, a protective effect of Impella on renal organ perfusion could recently be demonstrated. However, data identifying early risk predictors for developing AKI during Impella support in CS are rare. Data of hemodynamics and renal function from 50 Impella patients (January 2020 and February 2022) with MI-related CS (SCAI stage C), were retrospectively analyzed using e.g. multivariate logistic regression analysis as well as Kaplan-Meier curves and Cox regression analysis. 30 patients (60%) developed AKI. Central venous pressure as an indicator for venous congestion (OR 1.216, p = 0.02), GFR at admission indicating existing renal damage (OR 0.928, p = 0.002), and reduced central venous oxygen saturation (SvO2) as a marker for decreased tissue perfusion (OR 0.930, p = 0.029) were independently associated with developing an AKI. The 30-day mortality rate was significantly higher in patients with AKI stage 3 (Stage 1: 0%, Stage 2: 0%, Stage 3; 41.6%, p = 0.014) while AKI stage 3 (HR 0.095, p = 0.026) and norepinephrine dosage (HR 1.027, p = 0.008) were independent predictors for 30-day mortality. AKI as a complication of MI-related CS occurs frequently with a major impact on prognosis. Venous congestion, reduced tissue perfusion, and an already impaired renal function are independent predictors of AKI. Thus, timely diagnostics and a focused treatment of the identified factors could improve prognosis and outcome.
Keywords: Acute kidney injury (AKI); Cardiogenic shock; Left ventricular Impella; Predictors of AKI.
© 2024. The Author(s).
Conflict of interest statement
B.M. received research funding from Abiomed; J.K., G.C., B.S., and B.M. receive speaker’s honoraria from Abiomed; no other of the remaining authors declared any disclosures.
Figures



Similar articles
-
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.Circulation. 2024 Dec 17;150(25):1990-2003. doi: 10.1161/CIRCULATIONAHA.124.072370. Epub 2024 Oct 27. Circulation. 2024. PMID: 39462276 Free PMC article. Clinical Trial.
-
Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience.Eur Heart J Acute Cardiovasc Care. 2019 Jun;8(4):338-349. doi: 10.1177/2048872618805486. Epub 2018 Nov 7. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 30403366 Free PMC article.
-
Impact of microaxillar mechanical left ventricular support on renal resistive index in patients with cardiogenic shock after myocardial infarction: a pilot trial to predict renal organ dysfunction in cardiogenic shock.Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(2):158-163. doi: 10.1177/2048872619860218. Epub 2019 Jun 27. Eur Heart J Acute Cardiovasc Care. 2020. PMID: 31246097 Free PMC article.
-
Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock-a critical appraisal of current data.Clin Res Cardiol. 2019 Nov;108(11):1249-1257. doi: 10.1007/s00392-019-01458-2. Epub 2019 Mar 21. Clin Res Cardiol. 2019. PMID: 30900010
-
Comparative Healthcare Resource Utilization of Percutaneous Mechanical Circulatory Support Using Impella Versus Intra-aortic Balloon Pump Use for Patients With Acute Coronary Syndrome and Cardiogenic Shock Undergoing Percutaneous Coronary Interventions: Insights From National Inpatient Sample.Curr Probl Cardiol. 2024 Jan;49(1 Pt A):102053. doi: 10.1016/j.cpcardiol.2023.102053. Epub 2023 Aug 26. Curr Probl Cardiol. 2024. PMID: 37640173 Review.
Cited by
-
Cardiac index, SvO2 or pCO2 gap may determine benefit from ECMO in cardiogenic shock: post-hoc analysis of the multicenter, randomized ECMO-CS trial.Crit Care. 2025 Jul 14;29(1):303. doi: 10.1186/s13054-025-05513-5. Crit Care. 2025. PMID: 40660350 Free PMC article. Clinical Trial.
-
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.Circulation. 2024 Dec 17;150(25):1990-2003. doi: 10.1161/CIRCULATIONAHA.124.072370. Epub 2024 Oct 27. Circulation. 2024. PMID: 39462276 Free PMC article. Clinical Trial.
-
Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.Curr Heart Fail Rep. 2025 Jun 25;22(1):19. doi: 10.1007/s11897-025-00706-z. Curr Heart Fail Rep. 2025. PMID: 40560292 Review.
-
Unexpectedly high rate of unrecognized acute kidney injury and its trend over the past 14 years.Sci Rep. 2025 Feb 21;15(1):6305. doi: 10.1038/s41598-025-88732-8. Sci Rep. 2025. PMID: 39984512 Free PMC article.
-
Evaluating gender-based disparities in the outcomes of impella use in acute myocardial infarction patients with cardiogenic shock; insights from real-world global data.BMC Cardiovasc Disord. 2025 Jul 28;25(1):548. doi: 10.1186/s12872-025-04999-9. BMC Cardiovasc Disord. 2025. PMID: 40721725 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources